Rapt Therapeutics brings to GSK ozureprubart, a long-acting antibody that inhibits the validated immunology target immunoglobulin E (IgE). If GSK is able to bring this drug to the market, it would complete with the blockbuster Genentech and Novartis allergy drug Xolair.
The post GSK Grows in Immunology, Buying Rapt Therapeutics and Food Allergy Drug in $2.2B Deal appeared first on MedCity News.
